Waters (WAT) Q3 2026 Earnings Call: Q&A Summary

Q: Tycho Peterson with Jefferies asked what it takes to get the acquired BD business back to its longer-term algo and what would drive the combined company to high single-digit growth versus the mid-single-digit starting point.

A: Udit Batra, President and Chief Executive Officer, answered that the second-half exit rates of 5% for acquired businesses and 9% for legacy Waters provide a solid starting point, with upside coming from stronger pricing, new product momentum, reshoring orders, AI benefits, and a stabilizing China market.

Q: Tycho Peterson with Jefferies asked why fourth quarter earnings were not raised higher given the revenue beat and how to think about leverage for next year.

A: Amol Chaubal, Senior Vice President and Chief Financial Officer, answered that about one-third of the incremental gross margin goes to commissions and variable bonuses, while the remaining two-thirds are reinvested into high-growth programs like rapid sterility and proteomics.

Q: Vijay Kumar with Evercore ISI asked whether AI is incremental to legacy growth assumptions and if there is a way to quantify its revenue contribution.

A: Udit Batra, President and Chief Executive Officer, answered that while AI is driving tangible benefits through features like anomaly detection and peak integration in Empower, it is still too early to explicitly quantify the exact revenue impact.

Q: Vijay Kumar with Evercore ISI asked about the margin assumptions for 2027 and whether reinvestments offset synergy math.

A: Amol Chaubal, Senior Vice President and Chief Financial Officer, answered that the first six weeks of BD were not in the 2026 base and act as a 70 basis point headwind to next year's margins, which alongside cost synergies supports the starting 29.2% operating margin assumption.

Q: Doug Schenkel with UBS asked if the guidance philosophy is changing for 2027 and whether there is scope for meaningful upside to free cash flow estimates.

A: Udit Batra, President and Chief Executive Officer, answered that the guidance philosophy remains unchanged to set ambitious targets and step-by-step overcome them. Amol Chaubal added that free cash flow conversion will approach 100% of adjusted net income over time as integration costs fade and working capital normalizes.

Q: Dan Brennan with TD Cowen asked for color on how the quarter came in for BD, any backlog built during the shift, and granularity heading into year-end.

A: Udit Batra, President and Chief Executive Officer, answered that the business orchestrated a spot landing by lowering trade inventory, while flow reagents grew high single digits, China returned to growth, and strong commercial momentum supports the fourth quarter.

Q: Jack Meehan with Operon Research asked whether the HPV partnerships with National Labs displace incumbents or augment capacity and why they chose the BD core.

A: Udit Batra, President and Chief Executive Officer, answered that the national labs are adding BD cores initially for the HPV assay to expand access, rather than replacing existing equipment.

Q: Jack Meehan with Operon Research asked how revenue synergies are factored into the 2027 framework.

A: Amol Chaubal, Senior Vice President and Chief Financial Officer, answered that the starting assumption includes another $60 million added in 2027 over the $50 million in 2026, consistent with the original 5-year model.

Q: Dave Westenberg with Piper Sandler asked about what drove the flow reagent growth, the A7 replacement cycle, and how flow cytometry fits with AI.

A: Udit Batra, President and Chief Executive Officer, answered that flow reagent growth was driven by pricing, e-commerce, and specialized reagents, and that the A7 improves reproducibility for demanding AI-enabled platforms like IMU Biosciences.

Q: Dan Leonard with RBC Capital Markets asked about the outlook for China broadly and in diagnostics as DRG headwinds lap in the fourth quarter.

A: Udit Batra, President and Chief Executive Officer, answered that legacy China is growing 20% with localized portfolios driving bioscience growth, and that DRG headwinds will be fully in the baseline starting in the fourth quarter.